Analysts Set Cencora, Inc. (NYSE:COR) Target Price at $373.25

Shares of Cencora, Inc. (NYSE:COR) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $373.25.

Several brokerages have commented on COR. Robert W. Baird set a $392.00 price target on shares of Cencora in a report on Tuesday, December 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. JPMorgan Chase & Co. upped their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Wells Fargo & Company boosted their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th.

Insider Activity

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total value of $1,750,221.20. Following the completion of the transaction, the chief executive officer directly owned 68,059 shares in the company, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 20,317 shares of company stock valued at $7,009,260. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Several institutional investors have recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC raised its position in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. IAG Wealth Partners LLC bought a new position in Cencora in the third quarter worth about $30,000. Cloud Capital Management LLC bought a new stake in Cencora during the 3rd quarter valued at approximately $31,000. Caitlin John LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $31,000. Finally, Vermillion & White Wealth Management Group LLC raised its position in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.3%

COR stock opened at $338.87 on Tuesday. The stock has a 50-day simple moving average of $349.59 and a two-hundred day simple moving average of $316.70. Cencora has a twelve month low of $225.75 and a twelve month high of $377.54. The firm has a market capitalization of $65.74 billion, a PE ratio of 42.63, a PEG ratio of 1.61 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. Cencora’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.